Although the studies in patients with T2DM are yet in an incipient phase, FGF19 seems to be a promising and well-tolerated therapeutic candidate for NASH, having already collected some evidence pointing towards its potential to reduce LFC, fibrosis-related serum biomarkers, and liver enzyme levels [137,138,139,140]. This evidence concerns the gene FGF19 and type 2 diabetes mellitus.